Overexpression of periostin is significantly correlated to the tumor angiogenesis and poor prognosis in patients with esophageal squamous cell carcinoma

International Journal of Clinical and Experimental Pathology

Volumn 7, Issue 2, 2014, Pages 593-601

  Wang, Wei ^a   Sun, Qi Kai ^a   He, Yi Fu ^a   Ma, Dong Chun ^a   Xie, Ming Ran ^a   Ji, Chu Shu ^a   Hu, Bing ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

Angiogenesis; Esophageal squamous cell carcinoma; Periostin; Prognosis

Indexed keywords

CELL ADHESION MOLECULE; POSTN PROTEIN, HUMAN; TRANSCRIPTION FACTOR RUNX2; TUMOR MARKER; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ANGIOGENESIS; ARTICLE; CANCER STAGING; CELL DIFFERENTIATION; CHEMISTRY; CHI SQUARE DISTRIBUTION; DISEASE COURSE; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS TUMOR; FEMALE; HUMAN; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; MALE; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; SQUAMOUS CELL CARCINOMA; TUMOR INVASION; UPREGULATION; VASCULARIZATION;

ANGIOGENESIS; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; PERIOSTIN; PROGNOSIS;

CARCINOMA, SQUAMOUS CELL; CELL ADHESION MOLECULES; CELL DIFFERENTIATION; CHI-SQUARE DISTRIBUTION; DISEASE PROGRESSION; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84907714997     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Parkin DM, Bray F, Ferlay J and Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108
2. Kamangar F, Dores GM and Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006; 24: 2137-2150
3. Sano A, Kato H, Sakurai S, Sakai M, Tanaka N, Inose T, Saito K, Sohda M, Nakajima M, Nakajima T and Kuwano H. CD24 expression is a novel prognostic factor in esophageal squamous cell carcinoma. Ann Surg Oncol 2009; 16: 506-514
4. Mariette C, Balon JM, Piessen G, Fabre S, Van Seuningen I and Triboulet JP. Pattern of recurrence following complete resection of esophageal carcinoma and factors predictive of recurrent disease. Cancer 2003; 97: 1616-1623
5. Ren Y, Cao B, Law S, Xie Y, Lee PY, Cheung L, Chen Y, Huang X, Chan HM, Zhao P, Luk J, Vande Woude G and Wong J. Hepatocyte growth factor promotes cancer cell migration and angiogenic factors expression: a prognostic marker of human esophageal squamous cell carcinomas. Clin Cancer Res 2005; 11: 6190-6197
6. Takeshita S, Kikuno R, Tezuka K and Amann E. Osteoblast-specific factor 2: cloning of a putative bone adhesion protein with homology with the insect protein fasciclin I. Biochem J 1993; 294: 271-278
7. Gillan L, Matei D, Fishman DA, Gerbin CS, Karlan BY and Chang DD. Periostin secreted by epithelial ovarian carcinoma is a ligand for alpha(V)beta(3) and alpha(V)beta(5) integrins and promotes cell motility. Cancer Res 2002; 62: 5358-5364
8. Bao S, Ouyang G, Bai X, Huang Z, Ma C, Liu M, Shao R, Anderson RM, Rich JN and Wang XF. Periostin potently promotes metastatic growth of colon cancer by augmenting cell survival via the Akt/PKB pathway. Cancer Cell 2004; 5: 329-339
9. Shao R, Bao S, Bai X, Blanchette C, Anderson RM, Dang T, Gishizky ML, Marks JR and Wang XF. Acquired expression of periostin by human breast cancers promotes tumor angiogenesis through up-regulation of vascular endothelial growth factor receptor 2 expression. Mol Cell Biol 2004; 24: 3992-4003
10. Ismail RS, Baldwin RL, Fang J, Browning D, Karlan BY, Gasson JC and Chang DD. Differential gene expression between normal and tumor-derived ovarian epithelial cells. Cancer Res 2000; 60: 6744-6749
11. Chang Y, Lee TC, Li JC, Lai TL, Chua HH, Chen CL, Doong SL, Chou CK, Sheen TS and Tsai CH. Differential expression of osteoblast-specific factor 2 and polymeric immunoglobulin receptor genes in nasopharyngeal carcinoma. Head Neck 2005; 27: 873-882
12. Fluge O, Bruland O, Akslen LA, Lillehaug JR and Varhaug JE. Gene expression in poorly differentiated papillary thyroid carcinomas. Thyroid 2006; 16: 161-175
13. Kudo Y, Ogawa I, Kitajima S, Kitagawa M, Kawai H, Gaffney PM, Miyauchi M and Takata T. Periostin promotes invasion and anchorage-independent growth in the metastatic process of head and neck cancer. Cancer Res 2006; 66: 6928-6935
14. Siriwardena BS, Kudo Y, Ogawa I, Kitagawa M, Kitajima S, Hatano H, Tilakaratne WM, Miyauchi M and Takata T. Periostin is frequently overexpressed and enhances invasion and angiogenesis in oral cancer. Br J Cancer 2006; 95: 1396-1403
15. Baril P, Gangeswaran R, Mahon PC, Caulee K, Kocher HM, Harada T, Zhu M, Kalthoff H, Crnogorac-Jurcevic T and Lemoine NR. Periostin promotes invasiveness and resistance of pancreatic cancer cells to hypoxia-induced cell death: role of the beta4 integrin and the PI3k pathway. Oncogene 2007; 26: 2082-2094
16. Erkan M, Kleeff J, Gorbachevski A, Reiser C, Mitkus T, Esposito I, Giese T, Buchler MW, Giese NA and Friess H. Periostin creates a tumor-supportive microenvironment in the pancreas by sustaining fibrogenic stellate cell activity. Gastroenterology 2007; 132: 1447-1464
17. Kwon YJ, Lee SJ, Koh JS, Kim SH, Kim YJ and Park JH. Expression patterns of aurora kinase B, heat shock protein 47, and periostin in esophageal squamous cell carcinoma. Oncol Res 2009; 18: 141-151
18. Ouyang G, Liu M, Ruan K, Song G, Mao Y and Bao S. Upregulated expression of periostin by hypoxia in non-small-cell lung cancer cells promotes cell survival via the Akt/PKB pathway. Cancer Lett 2009; 281: 213-219
19. Lv Y, Wang W, Jia WD, Sun QK, Huang M, Zhou HC, Xia HH, Liu WB, Chen H, Sun SN and Xu GL. High preoparative levels of serum periostin are associated with poor prognosis in patients with hepatocellular carcinoma after hepatectomy. Eur J Surg Oncol 2013; 39: 1129-1135
20. Lv Y, Wang W, Jia WD, Sun QK, Li JS, Ma JL, Liu WB, Zhou HC, Ge YS, Yu JH, Xia HH and Xu GL. High-level expression of periostin is closely related to metastatic potential and poor prognosis of hepatocellular carcinoma. Med Oncol 2013; 30: 385
21. Michaylira CZ, Wong GS, Miller CG, Gutierrez CM, Nakagawa H, Hammond R, Klein-Szanto AJ, Lee JS, Kim SB, Herlyn M, Diehl JA, Gimotty P and Rustgi AK. Periostin, a cell adhesion molecule, facilitates invasion in the tumor microenvironment and annotates a novel tumor-invasive signature in esophageal cancer. Cancer Res 2010; 70: 5281-5292
22. Wong GS, Lee JS, Park YY, Klein-Szanto AJ, Waldron TJ, Cukierman E, Herlyn M, Gimotty P, Nakagawa H and Rustgi AK. Periostin cooperates with mutant p53 to mediate invasion through the induction of STAT1 signaling in the esophageal tumor microenvironment. Oncogenesis 2013; 2: e59
23. Luo JH, Zhou J and Gao Y. Correlation between periostin and SNCG and esophageal cancer invasion, infiltration and apoptosis. Asian Pac J Trop Med 2013; 6: 516-519
24. Butler JM, Kobayashi H and Rafii S. Instructive role of the vascular niche in promoting tumour growth and tissue repair by angiocrine factors. Nat Rev Cancer 2010; 10: 138-146
25. Hanahan D and Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674
26. Kitadai Y, Haruma K, Tokutomi T, Tanaka S, Sumii K, Carvalho M, Kuwabara M, Yoshida K, Hirai T, Kajiyama G and Tahara E. Significance of vessel count and vascular endothelial growth factor in human esophageal carcinomas. Clin Cancer Res 1998; 4: 2195-2200
27. Vallbohmer D, Peters JH, Kuramochi H, Oh D, Yang D, Shimizu D, DeMeester SR, Hagen JA, Chandrasoma PT, Danenberg KD, Danenberg PV and DeMeester TR. Molecular determinants in targeted therapy for esophageal adenocarcinoma. Arch Surg 2006; 141: 476-481; discussion 481-472
28. Oshima Y, Yajima S, Yamazaki K, Matsushita K, Tagawa M and Shimada H. Angiogenesis-related factors are molecular targets for diagnosis and treatment of patients with esophageal carcinoma. Ann Thorac Cardiovasc Surg 2010; 16: 389-393
29. Kozlowski M, Kowalczuk O, Milewski R, Chyczewski L, Niklinski J and Laudanski J. Serum vascular endothelial growth factors C and D in patients with oesophageal cancer. Eur J Cardiothorac Surg 2010; 38: 260-267
30. Li G, Jin R, Norris RA, Zhang L, Yu S, Wu F, Markwald RR, Nanda A, Conway SJ, Smyth SS and Granger DN. Periostin mediates vascular smooth muscle cell migration through the integrins alphavbeta3 and alphavbeta5 and focal adhesion kinase (FAK) pathway. Atherosclerosis 2010; 208: 358-365
31. Utispan K, Sonongbua J, Thuwajit P, Chau-In S, Pairojkul C, Wongkham S and Thuwajit C. Periostin activates integrin alpha5beta1 through a PI3K/AKTdependent pathway in invasion of cholangiocarcinoma. Int J Oncol 2012; 41: 1110-1118